November 2025 FDA Recall Bisoprolol Fumarate And Hydrochlorothiazide by Glenmark Pharmaceuticals Inc., Usa
D-0199-2026 - Cross Contamination with Other Products

This Class III drug recall was voluntarily initiated by Glenmark Pharmaceuticals Inc., Usa on November 21, 2025 for the product Bisoprolol Fumarate And Hydrochlorothiazide. The FDA reported the reason for recall as cross contamination with other products. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0199-2026

Reason for Recall
Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
Initiated
11-21-2025
Reported
12-10-2025
Quantity
11,136 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Glenmark Pharmaceuticals Inc., USA
Nationwide in the USA
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a) 30-count bottles, NDC-68462-878-30; (b) 100-count bottle, NDC-68462-878-01; (c) 500-count bottles, NDC-68462-878-05; Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, Inda. Manufactured for: Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430.

Batch or Lot Expiration Information

Lot# : (a): Lot 17232401, exp 11/2025; Lot 17240974, exp 05/2026 (b): Lot 17232401, exp 11/2025; Lot 17240974, exp 05/2026 (c): Lot 17232401, exp 11/2025; Lot 17240974, exp 05/2026